REG - Fusion Antibodies - Total Voting Rights

Fusion AntibodiesAnnouncement

30/01/2026 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260130:nRSd1535Ra&default-theme=true

RNS Number : 1535R  Fusion Antibodies PLC  30 January 2026

30 January 2026

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Total Voting Rights

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that the issued share capital of the Company at the
date of this announcement comprises 125,021,878 ordinary shares of 4 pence
each with one voting right per share ("Ordinary Shares"). The Company does not
hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary
Shares and voting rights in the Company is 125,021,878.

 

The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

 Fusion Antibodies plc                                                             www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Fusion Antibodies interactive investor hub                             https://investorhub.fusionantibodies.com/
                                                                        (https://investorhub.fusionantibodies.com/)

 Allenby Capital Limited                                                Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                             Tel: +44 (0) 207 186 9952

 Walbrook PR                                 Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                                         Mob: +44 (0)7876 741
                                                                        001

About Fusion Antibodies plc

 

Fusion Antibodies plc is a Contract Research Organisation (CRO) located in
Northern Ireland that offers an integrated end-to-end range of antibody
discovery, engineering and expression services for all stages of human
therapeutic, veterinary therapeutic and diagnostic antibody development.

 

The range of services offered includes antibody discovery/generation,
development, characterisation, optimisation, and small-scale production. In
addition, the Company also offers antigen design, antigen expression, antibody
purification and sequencing, antibody humanisation using Fusion's proprietary
CDRx(TM) platform and cell line development, producing antibody generating
stable cell lines optimised for use downstream by the customer to produce
material for clinical trials. Since 2012, the Company has successfully
sequenced and expressed many thousands of antibodies and successfully
completed over 290 humanisation projects for its international customer base,
which has included eight of the top 10 global pharmaceutical companies by
revenue.

 

At every stage, our client's vision is central to how we work in combining the
latest technological advances with cutting edge science. In this work our
world-class discovery (OptiMAL® and OptiPhage(TM)), humanization and antibody
optimization platforms harness the power of natural somatic hypermutation
(SHM) to ensure the best molecule goes to the clinic.

 

Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech
companies get to the clinic more effectively, using molecules with optimized
therapeutic profile and enhanced potential for successful development and
approval and, ultimately, on speeding up the drug discovery and development
process. Our Integrated Therapeutic Antibody Services ("ITA") offering
enhances the efficiency of this process by providing a continuous service
offering from as early as target nomination to as far as a stable cell line.
Fusion's use of SHM to create a fully human antibody library to capture the
human antibody repertoire addresses a continuing market need in antibody
discovery.

 

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and
growth rate in the sector, with the market valued at $253 billion in 2024 and
forecast to reach nearly $500 billion by 2029.  From 2020 to 2024 there have
been 63 antibody therapeutics granted approval in either the USA or the EU, of
which 30 were for cancer and there were nine antibodies each with sales of
more than $5 billion in 2023.

 

While therapeutic antibodies are our primary focus, all the services are
directly applicable to the Diagnostic sector and also the new, more embryonic
veterinary markets and diversification into these markets gives the Company
further growth opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBSGDBGSXDGLG



            Copyright 2019 Regulatory News Service, all rights reserved